Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week CongressBusiness Wire • 10/25/24
Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market AwaitsThe Motley Fool • 10/24/24
Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual MeetingBusiness Wire • 10/18/24
Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to NoteZacks Investment Research • 10/14/24
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest?Zacks Investment Research • 09/26/24
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis ConferenceBusiness Wire • 09/26/24
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 09/23/24
Vertex Pharmaceuticals Incorporated (VRTX) Management presents at Cantor Global Healthcare Conference (Transcript)Seeking Alpha • 09/17/24
Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain DrugSeeking Alpha • 09/15/24
Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?Zacks Investment Research • 09/13/24
Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?Zacks Investment Research • 09/11/24